Cargando…

Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma

SIMPLE SUMMARY: Survival rates in metastatic renal cell carcinoma (RCC) are still low despite novel therapies available. Thus, knowledge of molecular characteristics of distant metastases is important for personalized treatment strategies. Therefore, we investigated the genetic landscape of metastas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sauter-Meyerhoff, Carolin, Bohnert, Regina, Mazzola, Pascale, Stühler, Viktoria, Kandabarau, Siarhei, Büttner, Florian A., Winter, Stefan, Herrmann, Lisa, Rausch, Steffen, Hennenlotter, Jörg, Fend, Falko, Scharpf, Marcus, Stenzl, Arnulf, Ossowski, Stephan, Bedke, Jens, Schwab, Matthias, Schaeffeler, Elke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699544/ https://www.ncbi.nlm.nih.gov/pubmed/34944839 http://dx.doi.org/10.3390/cancers13246221

Ejemplares similares

MCT4 surpasses the prognostic relevance of the ancillary protein CD147 in clear cell renal cell carcinoma
por: Fisel, Pascale, et al.
Publicado: (2015)

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
por: Reustle, Anna, et al.
Publicado: (2020)

Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma
por: Büttner, Florian, et al.
Publicado: (2018)

Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases
por: Maas, Moritz, et al.
Publicado: (2023)

Nicotinamide‐N‐methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma
por: Reustle, Anna, et al.
Publicado: (2022)

Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes
por: Winter, Stefan, et al.
Publicado: (2016)

The prognostic value of fat invasion and tumor expansion in the hilar veins in pT3a renal cell carcinoma
por: Stühler, Viktoria, et al.
Publicado: (2021)

Role of the Systemic Immune-Inflammation Index in Patients with Metastatic Renal Cell Carcinoma Treated with First-Line Ipilimumab plus Nivolumab
por: Stühler, Viktoria, et al.
Publicado: (2022)

Real world data on IO-based therapy for metastatic renal cell carcinoma
por: Stühler, Viktoria, et al.
Publicado: (2022)

A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy
por: Büttner, Florian A., et al.
Publicado: (2022)

Hypertonicity-Affected Genes Are Differentially Expressed in Clear Cell Renal Cell Carcinoma and Correlate with Cancer-Specific Survival
por: Kandabarau, Siarhei, et al.
Publicado: (2019)

Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies
por: Stühler, Viktoria, et al.
Publicado: (2022)

Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC
por: Ribback, Silvia, et al.
Publicado: (2021)

Impact of an Altered Wnt1/β-Catenin Expression on Clinicopathology and Prognosis in Clear Cell Renal Cell Carcinoma
por: Kruck, Stephan, et al.
Publicado: (2013)

Utility of pT3 substaging in lymph node-negative urothelial carcinoma of the bladder: do pathologic parameters add to prognostic sub-stratification?
por: Maas, Moritz, et al.
Publicado: (2021)

A Rare Case of Synchronous Renal Cell Carcinoma of the Bladder Presenting With Gross Hematuria
por: Kruck, Stephan, et al.
Publicado: (2013)

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2018)

Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy
por: Thaiss, Wolfgang M., et al.
Publicado: (2022)

Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder?
por: Bier, Simone, et al.
Publicado: (2018)

Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity
por: Stühler, Viktoria, et al.
Publicado: (2016)

Circulating tumor cells and their role in prostate cancer
por: Maas, Moritz, et al.
Publicado: (2019)

Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases
por: Aufderklamm, Stefan, et al.
Publicado: (2021)

Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer
por: Hegemann, Miriam, et al.
Publicado: (2019)

A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies
por: Gürgen, Dennis, et al.
Publicado: (2022)

Androgen receptor overexpression in prostate cancer in type 2 diabetes
por: Lutz, Stefan Zoltán, et al.
Publicado: (2017)

Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy
por: Fisel, Pascale, et al.
Publicado: (2018)

Assessment of a new point-of-care system for detection of prostate specific antigen
por: Rausch, Steffen, et al.
Publicado: (2016)

p53 is functionally inhibited in clear cell renal cell carcinoma (ccRCC): a mechanistic and correlative investigation into genetic and molecular characteristics
por: Diesing, Karoline, et al.
Publicado: (2021)

Versatility and clinical effectiveness of a synthetic sealing hemostatic patch as alternative to parenchyma suturing in laparoscopic partial nephrectomy
por: Erne, Eva, et al.
Publicado: (2021)

Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes
por: Franko, Andras, et al.
Publicado: (2020)

Increased Expressions of Matrix Metalloproteinases (MMPs) in Prostate Cancer Tissues of Men with Type 2 Diabetes
por: Franko, Andras, et al.
Publicado: (2020)

Urinary Tract Tumor Organoids Reveal Eminent Differences in Drug Sensitivities When Compared to 2-Dimensional Culture Systems
por: Wei, Yi, et al.
Publicado: (2022)

CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?
por: Geng, Ruizhi, et al.
Publicado: (2022)

No association of genetic variants in TLR4, TNF-α, IL10, IFN-γ, and IL37 in cytomegalovirus-positive renal allograft recipients with active CMV infection—Subanalysis of the prospective randomised VIPP study
por: Mazzola, Pascale, et al.
Publicado: (2021)

Economic aspects of bladder cancer: what are the benefits and costs?
por: Sievert, K. D., et al.
Publicado: (2009)

Pharmacogenomics: a key component of personalized therapy
por: Schwab, Matthias, et al.
Publicado: (2012)

Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2015)

Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma
por: Aicher, Wilhelm K., et al.
Publicado: (2021)

Insulin Receptor Isoforms A and B as well as Insulin Receptor Substrates-1 and -2 Are Differentially Expressed in Prostate Cancer
por: Heni, Martin, et al.
Publicado: (2012)

Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation
por: Harland, Niklas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kfnncq9jjgje2vt4egeuduroig